| Browse All

Clene Inc. (CLNN)

Consumer Defensive | Packaged Foods | Salt Lake City, United States | NasdaqCM
6.31 USD -0.04 (-0.630%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 6.40 +0.09 (1.426%) ⇧ (April 17, 2026, 4:36 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 4:18 p.m. EDT

CLNN appears to be a highly volatile and fundamentally weak stock with a significant negative earnings outlook and a lack of dividend history. The recent price movements show a mix of upward and downward trends, but the overall trajectory remains uncertain. The stock has a low market cap and high debt-to-equity ratio, which makes it risky for short-term trading. Long-term investors should be cautious, as the company's fundamentals are not strong, and there is no indication of sustainable growth or profitability. The stock's low price-to-book ratio and negative return on assets suggest potential undervaluation, but this may not translate into value unless the company improves its financial performance significantly.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.130162
AutoETS0.130243
MSTL0.132470
AutoTheta0.289657

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 80%
H-stat 0.65
Ljung-Box p 0.000
Jarque-Bera p 0.309
Excess Kurtosis -1.06
Attribute Value
Sector Consumer Defensive
Revenue per Share 0.02
Market Cap 74,321,120
Forward P/E -4.34
Beta 0.62
Previous Name Clene Nanomedicine Inc.
Website https://clene.com

Info Dump

Attribute Value
52 Week Change 1.102649
Address1 6,550 South Millrock Drive
Address2 Suite G50
All Time High 356.4
All Time Low 2.28
Ask 6.55
Ask Size 1
Average Daily Volume10 Day 83,130
Average Daily Volume3 Month 83,127
Average Volume 83,127
Average Volume10Days 83,130
Beta 0.62
Bid 6.2
Bid Size 1
Book Value -1.621
City Salt Lake City
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 6.31
Current Ratio 0.833
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 6.73
Day Low 6.28
Display Name Clene
Earnings Timestamp End 1,755,088,200
Earnings Timestamp Start 1,755,088,200
Ebitda -21,588,000
Ebitda Margins 0.0
Enterprise To Ebitda -4.206
Enterprise To Revenue 454.026
Enterprise Value 90,805,120
Eps Current Year -1.67
Eps Forward -1.455
Eps Trailing Twelve Months -2.65
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 5.295
Fifty Day Average Change 1.0149999
Fifty Day Average Change Percent 0.19169025
Fifty Two Week Change Percent 110.2649
Fifty Two Week High 13.5
Fifty Two Week High Change -7.19
Fifty Two Week High Change Percent -0.5325926
Fifty Two Week Low 2.28
Fifty Two Week Low Change 4.0299997
Fifty Two Week Low Change Percent 1.7675438
Fifty Two Week Range 2.28 - 13.5
Financial Currency USD
First Trade Date Milliseconds 1,539,869,400,000
Float Shares 8,433,032
Forward Eps -1.455
Forward P E -4.3367696
Free Cashflow -10,136,125
Full Exchange Name NasdaqCM
Full Time Employees 76
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.785
Gross Profits 157,000
Has Pre Post Market Data 1
Held Percent Insiders 0.26645002
Held Percent Institutions 0.22182
Implied Shares Outstanding 11,778,307
Industry Packaged Foods
Industry Disp Packaged Foods
Industry Key packaged-foods
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,720,656,000
Last Split Factor 1:20
Long Business Summary Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Long Name Clene Inc.
Market us_market
Market Cap 74,321,120
Market State CLOSED
Max Age 86,400
Message Board Id finmb_339429732
Most Recent Quarter 1,767,139,200
Name Change Date 2,026-04-16
Net Income To Common -26,173,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 75,027,815
Number Of Analyst Opinions 6
Open 6.39
Operating Cashflow -18,546,000
Operating Margins -97.337654
Payout Ratio 0.0
Phone 801 676 9695
Post Market Change 0.09000015
Post Market Change Percent 1.4263098
Post Market Price 6.4
Post Market Time 1,776,458,193
Prev Name Clene Nanomedicine Inc.
Previous Close 6.35
Price Eps Current Year -3.778443
Price Hint 2
Price To Book -3.8926587
Price To Sales Trailing12 Months 371.6056
Profit Margins 0.0
Quick Ratio 0.536
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.04
Regular Market Change Percent -0.629921
Regular Market Day High 6.73
Regular Market Day Low 6.28
Regular Market Day Range 6.28 - 6.73
Regular Market Open 6.39
Regular Market Previous Close 6.35
Regular Market Price 6.31
Regular Market Time 1,776,456,001
Regular Market Volume 68,589
Return On Assets -0.63458997
Revenue Growth -0.154
Revenue Per Share 0.02
Sand P52 Week Change 0.36506534
Sector Consumer Defensive
Sector Disp Consumer Defensive
Sector Key consumer-defensive
Shares Outstanding 11,778,307
Shares Percent Shares Out 0.082600005
Shares Short 972,726
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 843,871
Short Name Clene Inc.
Short Percent Of Float 0.1137
Short Ratio 11.35
Source Interval 15
State UT
Symbol CLNN
Target High Price 48.0
Target Low Price 20.0
Target Mean Price 30.33333
Target Median Price 30.0
Total Cash 5,189,000
Total Cash Per Share 0.441
Total Debt 21,673,000
Total Revenue 200,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.65
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.07295
Two Hundred Day Average Change 0.23705006
Two Hundred Day Average Change Percent 0.03903376
Type Disp Equity
Volume 68,589
Website https://clene.com
Zip 84,121